Quest Diagnostics Incorporated

Quest Diagnostics Incorporated, headquartered in Secaucus, New Jersey, is one of the nation's largest clinical laboratory testing companies, delivering reference laboratory testing, infectious disease screening, clinical diagnostic analysis, and specialized esoteric testing services to federal healthcare agencies as a prime contractor on over 6,800 awards spanning four decades of federal work. The vendor competes exclusively full-and-open, with no set-aside designations across its federal portfolio—a positioning characteristic of large established vendors with substantial capacity to compete directly in unrestricted federal procurement.

Quest Diagnostics' customer footprint concentrates heavily in the Department of Veterans Affairs, which anchors roughly 50 percent of the vendor's combined federal potential value and reflects the company's dominant role as a reference laboratory testing provider to VA medical centers nationwide. Within VA, the top five Veterans Integrated Service Networks (VISNs 12, 8, 21, 6, and 17) account for approximately 70 percent of VA dollars, with VISN 12 alone representing $868.3 million in combined potential value across 71 awards. The Department of Health and Human Services Indian Health Service represents the second-largest customer base by award count (418 awards, $45.6 million), followed by the Department of the Army Medical Command (321 awards, $20.2 million) and the Department of Justice Bureau of Prisons (150-plus awards across multiple facilities). A significant secondary customer base spans federal research initiatives: the National Institutes of Health (including the National Heart, Lung and Blood Institute), the Centers for Disease Control and Prevention, and the Fred Hutchinson Cancer Center have engaged Quest Diagnostics or its subsidiary ExamOne for biomarker collection, home health assessments, and laboratory support on clinical research protocols funded by NIH grant programs.

The vendor's core capability footprint is anchored to the Medical Laboratory Testing and Analysis Services Federal Supply Schedule (FSS-621-II), a General Services Administration master contract vehicle that carries 4,961 task orders worth $1.47 billion in combined potential value. Beyond the GSA schedule, Quest Diagnostics holds numerous single-award indefinite-delivery blanket purchase agreements (BPAs) with individual VISNs, including a $24 million BPA with VISN 17 for South Texas Veterans Healthcare System reference laboratory testing (through April 2031), a $9.5 million BPA with VISN 17 for Texas Valley Coastal Bend services (through May 2031), and a $4.074 billion IDIQ with VISN 12 established July 1, 2026 under a sole-source justification to sustain existing testing operations during the network's transition to a new electronic health record system. Other significant vehicles include Blanket Purchase Agreement 15BNAS20A00000070 (1,539 task orders, $88 million combined value) and multiple Army IDIQs (DADA1003D0030 with 266 task orders; DADA1098D0001 with 216 task orders).

Activity trajectory shows decline over the past five years: 538 awards in FY2022 declined to 244 in FY2026 year-to-date, a 55 percent reduction across the five-year window. This decline reflects consolidation of individual task orders into larger standing agreements rather than loss of federal business; the combined potential value across all awards remains substantial at $3.48 billion, with $1.36 billion obligated to date. Recompete exposure in the next 24 months totals 131 awards with combined potential value of $113.7 million, representing routine turnover on quarterly and annual calls against standing BPA and schedule vehicles. The most significant recompete risk sits with the VISN 12 IDIQ and the Medical Laboratory Testing and Analysis Services schedule itself, which generate persistent task order activity.

Service Contract Inventory data (covering federal service contracts above the $150,000 threshold) shows SCI-reported invoicing of $141.8 million in FY2022, $57 million in FY2023, and $61.3 million in FY2024, declining notably year-over-year but stabilizing in FY2023–FY2024. These SCI figures represent a strict subset of Quest Diagnostics' total federal revenue and exclude goods, products, micro-purchases, classified work, and non-federal activity. The SCI dataset shows roughly 1,240 FTEs delivered to federal government in FY2022, declining to 137 in FY2023 and recovering modestly to 154 in FY2024; these trajectory changes likely reflect methodology shifts in FTE reporting rather than workforce contraction. Government-paid rates on SCI service contracts cluster tightly around $200/hour (10th percentile $199.96/hr, median $200.00/hr, 90th percentile $200.06/hr), reflecting standardized federal pricing under the GSA schedule's medical laboratory services framework.

The vendor operates as a pure prime contractor on federal awards; across all 6,834 awards in the source, 6,831 are structured as prime contracts or IDVs, with only three sub-award records (two contract sub-awards and one grant sub-award, all under large primes or grantees including Life Technologies Corporation and Fred Hutchinson Cancer Center). Quest Diagnostics does not report sub-engagement on SCI contracts. The corporate structure reveals 24 named subsidiaries, including Focus Diagnostics, Inc. (diagnostic test manufacturer), Hemocue, Inc. (point-of-care diagnostics), Unilab Corporation, Ameripath Inc., and Quest Diagnostics Nichols Institute—collectively these subsidiaries extend the parent's capability footprint to in-vitro diagnostics manufacturing, pathology services, and specialized reference laboratory operations.

The vendor's core competency concentration is pronounced: 6,305 of 6,834 awards carry NAICS code 621511 (Medical Laboratory Services), and 6,039 awards fall under Product and Service Code (PSC) "Reference Laboratory Testing." Secondary capability codes reflect pathology services (114 awards), medical managed healthcare (140 awards), and laboratory equipment and supplies (68 awards), confirming that Quest Diagnostics' federal business is predominantly laboratory-centric with ancillary pathology and equipment components.

Quest Diagnostics competes on a full-and-open, non-set-aside basis across all customer agencies—no 8(a), HUBZone, SDVOSB, or WOSB designations appear in the federal award record. The vendor's scale, 44-year federal contracting tenure (earliest award: December 1982), and established relationships with VA and Army medical systems position it as an incumbent prime across the federal medical laboratory testing market with minimal competitive risk from small-business preference categories or specialized set-aside vehicles. Recompete strategy for the vendor centers on sustaining task order flow under existing GSA schedule positions and renewing individual VISN BPAs as they approach completion; the planned competitive re-solicitation for the VISN 12 IDIQ within 12 to 18 months following EHR implementation represents the most material near-term competitive exposure.